ABT vs AMAT Stock Comparison

Scores Breakdown

Metric	ABT	AMAT
📈 Growth	22/30	28/30
💰 Profitability	17/20	18/20
🏦 Financial Health	15/20	16/20
💵 Valuation	12/20	14/20
⚠️ Risk (lower is better)	4/10	6/10
Overall Score	72/100	80/100

Side-by-Side Summaries

ABT Analysis	AMAT Analysis
📈 Growth & Financial Trajectory Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects). 💰 Margins & Cash Flow Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest. 🛡️ Balance Sheet & Liquidity Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience. ⚠️ Key Drivers & Risks Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios. Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.	📈 Growth & Financial Trajectory Over the eight quarters, AMAT shows a modest Revenues rise from about $7.05B in Q3 2024 to about $7.91B in Q2 2026, a roughly 12% increase, while Net Income grows from about $1.73B to about $2.81B, up roughly 62%. The trend is broadly positive despite mid-period volatility: Q4 2025 revenue dipped to about $6.8B before rebounding in early 2026. The trajectory suggests improving profitability even as quarterly results oscillate with industry cycles. 💰 Margins & Cash Flow Gross Margin has been resilient, typically in the mid-40s to low-50s, peaking around 51% in Q4 2025 and remaining near 50% in Q2 2026. Operating Margin runs in the low-to-mid 20s percent, with improvements during stronger quarters (roughly 25-32% range). Cash Flow from operating activities was positive in most quarters, supporting investment activity; however, the latest quarter shows a negative total cash flow (-$928M) driven by investing/financing outflows, highlighting cyclicality in capital allocation. 🛡️ Balance Sheet & Liquidity Assets run in the mid-$30s to low-$40s billions with equity typically in the low-to-mid $20s billions; current assets exceed current liabilities by a comfortable margin, yielding a healthy liquidity cushion. Liabilities are manageable, with limited long-term debt in several periods. ⚠️ Key Drivers & Risks Drivers: AI/Data Center demand for semiconductor equipment; ongoing capacity expansion in foundries. Risks: Semiconductor cycle sensitivity and valuation risk; potential margin compression if input costs or pricing pressure rise.

ABT Analysis

AMAT Analysis

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

📈 Growth & Financial Trajectory

Over the eight quarters, AMAT shows a modest Revenues rise from about $7.05B in Q3 2024 to about $7.91B in Q2 2026, a roughly 12% increase, while Net Income grows from about $1.73B to about $2.81B, up roughly 62%. The trend is broadly positive despite mid-period volatility: Q4 2025 revenue dipped to about $6.8B before rebounding in early 2026. The trajectory suggests improving profitability even as quarterly results oscillate with industry cycles.

💰 Margins & Cash Flow

Gross Margin has been resilient, typically in the mid-40s to low-50s, peaking around 51% in Q4 2025 and remaining near 50% in Q2 2026.
Operating Margin runs in the low-to-mid 20s percent, with improvements during stronger quarters (roughly 25-32% range).
Cash Flow from operating activities was positive in most quarters, supporting investment activity; however, the latest quarter shows a negative total cash flow (-$928M) driven by investing/financing outflows, highlighting cyclicality in capital allocation.

🛡️ Balance Sheet & Liquidity

Assets run in the mid-$30s to low-$40s billions with equity typically in the low-to-mid $20s billions; current assets exceed current liabilities by a comfortable margin, yielding a healthy liquidity cushion. Liabilities are manageable, with limited long-term debt in several periods.

⚠️ Key Drivers & Risks

Drivers: AI/Data Center demand for semiconductor equipment; ongoing capacity expansion in foundries.
Risks: Semiconductor cycle sensitivity and valuation risk; potential margin compression if input costs or pricing pressure rise.

Similar Companies

ABBV Score: 59 BSX Score: 81 ELV Score: 77 ISRG Score: 85 JNJ Score: 79 MDT Score: 67 TMO Score: 75 TSLA Score: 62

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"